CLBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cellebrite DI Ltd (CLBT) is not a strong buy for a beginner investor with a long-term focus at this moment. While the company has shown positive financial growth and analysts maintain a Buy rating, the lack of recent positive trading signals, bearish technical indicators, and a lack of significant news catalysts suggest that it is better to hold off on investing right now. The stock's price trend and limited upside potential in the short term make it less appealing for immediate entry.
The MACD is positive and expanding, indicating a potential upward momentum. However, the RSI is neutral at 52.073, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 12.218, and resistance is at 14.48. The stock is trading near its pivot level of 13.349, showing limited directional strength.
The company reported strong Q4 2025 financials with 18.13% YoY revenue growth, 10.34% YoY net income growth, and a gross margin increase to 84.71%. Analysts maintain a Buy rating, citing solid execution and AI as a growth driver.
Price targets have been lowered by multiple analysts due to market contraction. The stock's technical indicators are bearish, and there is no recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q4 2025, Cellebrite reported revenue growth of 18.13% YoY to $128.8M, net income growth of 10.34% YoY to $21.26M, and a stable EPS of $0.08. Gross margin improved slightly to 84.71%, reflecting strong operational efficiency.
Analysts from Needham, TD Cowen, and Lake Street maintain Buy ratings but have lowered price targets due to market contraction. The company is recognized for its solid financial performance and AI-driven growth potential.
